Vaxart Inc (VXRT) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Vaxart Inc stock $0.91, price $0.36, upside +152.8%, quality 69 out of 100. Rating: strongly undervalued. Calculated from audited financials with 22 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Vaxart Inc
VXRT · USCheap (60% below fair value), solid company and rising price: meets all 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.
How to read this chart
60‑month range $0.3000 – $9.21 · fair‑value band $0.6800 – $1.15 · the $0.3600 price screens below the $0.9100 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.
Every Wednesday you see whether Vaxart is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform.
Show moreShow less
The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical trial, to treat H1N1 Influenza; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.
The company also provides VAAST (Vector-Adjuvant-Antigen Standardized Technology) Platform, a unique modular vaccine platform. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral.
Vaxart, Inc. is headquartered in South San Francisco, California.
Stock analysis
Vaxart Inc (VXRT) currently trades at $0.3600, while our model-based Fair Value estimate is $0.9100, implying the stock looks roughly 60% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $1.46 per share, and 21 of the 22 models we run sit above the $0.3600 price.
Bear case: the Asset-Based group reads lowest at $0.1600, and 1 of the 22 models stay below the price. Data coverage for this calculation is low.
Scenario range: $0.6800 (bear) to $1.15 (bull), the price of $0.3600 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 69/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Vaxart Inc reported revenue of $237M in FY2025 versus $892K in FY2021, a compound +303.8%/yr. Reported net income was $16.3M in FY2025.
Key figures
Market cap $87.1M Micro · P/E ratio 2.1 · P/S ratio 0.36 · EPS (TTM) $0.1700 · Net margin 15.9% · Return on equity 67.0% · Return on assets (EBIT) −45.7% (5-year average) · Operating margin −48.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 49 out of 100 (low confidence).
What moves the price
The share trades about 55% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at 153%, VXRT screens cheaper than that median.
Fair Value models
All 22 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, one officer or director bought shares worth $6,500, on May 22, 2026.
- BuyW. Mark WatsonDirector2× since Nov 17, 2025: 30,000 shares, avg. $0.4900$14,700May 22, 2026
- BuyElaine J HeronDirector40,000 shares at $0.3984$15,936Nov 17, 2025
Plus 7 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Growth Forecast
Watch VXRT, get fair value alerts →
Earlier news
- Vaxart Appoints Retired Vice Admiral Raquel C. Bono, M.D., to Board of Directors
- Vaxart Q2 Earnings Call Highlights
- Vaxart outlines Phase IIb COVID-19 top line data in first half of 2027 backed by BARDA funding
- Vaxart Investors Reject Say-on-Pay as CEO Rules Out Reverse Split for Now
Compare Vaxart Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Quality Score by industry
- Return on equity by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs VXRT |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs VXRT |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs VXRT |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs VXRT |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs VXRT |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs VXRT |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs VXRT |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs VXRT |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs VXRT |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs VXRT |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Vaxart Inc (VXRT) overvalued or undervalued?
What is the fair value of VXRT?
What is the quality score of VXRT?
What is the price target for Vaxart Inc (VXRT)?
What is the Vaxart Inc stock forecast for 2026?
What is the revenue of Vaxart Inc (VXRT)?
What growth is priced into Vaxart Inc (VXRT)?
What discount rate (WACC) does the fair value of VXRT use?
What is a reverse DCF?
How much growth has Vaxart Inc (VXRT) delivered so far?
How fast is the sector of Vaxart Inc (VXRT) growing?
What is the free cash flow yield of Vaxart Inc (VXRT)?
What is the intrinsic value of Vaxart Inc (VXRT)?
Is Vaxart Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of VXRT?
How much is Vaxart Inc worth?
What do the bullish and bearish scenarios say about VXRT?
What is the P/E ratio of VXRT?
How solid is the balance sheet of Vaxart Inc (VXRT)?
How far is VXRT from its 52-week high?
Which stocks are comparable to Vaxart Inc?
Is Vaxart Inc stock attractive at the current price?
How is the fair value of VXRT calculated?
Is it still worth investing in stocks now?
What is the share price of Vaxart Inc (VXRT)?
What should I pay attention to with Vaxart Inc right now?
Key figures of Vaxart Inc
How large is the market capitalisation of Vaxart Inc (VXRT)?
What is the P/S ratio of Vaxart Inc (VXRT)?
What are the earnings per share of Vaxart Inc (VXRT)?
What is the net margin of Vaxart Inc (VXRT)?
What is the return on equity of Vaxart Inc (VXRT)?
What is the EBIT return on assets of Vaxart Inc (VXRT)?
What is the operating margin of Vaxart Inc (VXRT)?
How fast is revenue growing at Vaxart Inc (VXRT)?
How much net cash does Vaxart Inc (VXRT) hold?
Watch Vaxart Inc in the live analysis
One click puts Vaxart Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.